Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension

Journal of the American Society of Hypertension

Volumn 9, Issue 6, 2015, Pages 453-498

  Rosendorff, Clive ^a   Lackland, Daniel T ^a   Allison, Matthew ^a   Aronow, Wilbert S ^a   Black, Henry R ^a   Blumenthal, Roger S ^a   Cannon, Christopher P ^a   De Lemos, James A ^a   Elliott, William J ^a   Findeiss, Laura ^a   Gersh, Bernard J ^a   Gore, Joel M ^a   Levy, Daniel ^a   Long, Janet B ^a   O'Connor, Christopher M ^a   O'Gara, Patrick T ^a   Ogedegbe, Olugbenga ^a   Oparil, Suzanne ^a   White, William B ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

AHA scientific statements; Blood pressure; Coronary artery disease; Epidemiology; Hypertension; Secondary prevention

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CARVEDILOL; CHLORTALIDONE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; ESMOLOL; HYDRALAZINE; ISOSORBIDE DINITRATE; LISINOPRIL; METOPROLOL; METOPROLOL SUCCINATE; NITRIC ACID DERIVATIVE; PLACEBO; ROSUVASTATIN; SIMVASTATIN; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VASODILATOR AGENT;

ACUTE CORONARY SYNDROME; ADVERSE OUTCOME; ANTIHYPERTENSIVE THERAPY; BODY MASS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DIURETIC THERAPY; DRUG EFFICACY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; EPIDEMIOLOGICAL DATA; GENETIC ASSOCIATION; HEART FAILURE; HEART INFARCTION; HEMODYNAMICS; HUMAN; HYPERTENSION; MEDICAL SOCIETY; METABOLIC PARAMETERS; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; SCIENTIFIC LITERATURE; SECONDARY PREVENTION; SMOKING; STABLE ANGINA PECTORIS; SYSTOLIC BLOOD PRESSURE; TREATMENT INDICATION; COMORBIDITY; FEMALE; MALE; PRACTICE GUIDELINE; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; UNITED STATES;

AMERICAN HEART ASSOCIATION; ANTIHYPERTENSIVE AGENTS; COMORBIDITY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYPERTENSION; MALE; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK ASSESSMENT; SOCIETIES, MEDICAL; SURVIVAL RATE; UNITED STATES;

EID: 84942982991     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2015.03.002     Document Type: Article

References (284)

1. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL Jr, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007;115:2761-88.
2. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005;45:142-61.
3. Chobanian AV, Bakris GI, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al; the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.
4. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA 2002;287:1003-10.
5. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001;103:1245-9.
6. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Agespecific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies [published correction appears in Lancet. 2002;361:1060]. Lancet 2002;360:1903-13.
7. National Heart, Lung, and Blood Institute. Morbidity and Mortality: 2012 Chartbook on Cardiovascular, Lung and Blood Diseases. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health; 2012.
8. Lackland DT, Roccella EJ, Deutsch AF, Fornage M, George MG, Howard G, et al. American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; Council on Functional Genomics and Translational Biology. Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. Stroke 2014;45:315-53.
9. Miura K, Daviglus ML, Dyer AR, Liu K, Garside DB, Stamler J, et al. Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry. Arch Intern Med 2001;161:1501-8.
10. Yusuf S. Preventing vascular events due to elevated blood pressure. Circulation 2006;113:2166-8.
11. Lackland DT, Keil JE, Gazes PC, Hames CG, Tyroler HA. Outcomes of black and white hypertensive individuals after 30 years of follow-up. Clin Exp Hypertens 1995;17:1091-105.
12. Gazes PC, Lackland DT, Mountford WK, Gilbert GF, Harley RA. Comparison of cardiovascular risk factors for high brachial pulse pressure in blacks versus whites (Charleston Heart Study, Evans County Study, NHANES I and II Studies). Am J Cardiol 2008;102:1514-7.
13. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials: Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356:1955-64.
14. van Bemmel T, Gussekloo J, Westendorp RGJ, Blauw GJ. In a population-based prospective study, no association between high blood pressure and mortality after age 85 years. J Hypertens 2006;24:287-92.
15. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-98.
16. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-53.
17. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, et al; SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial: the SAVE Investigators. N Engl J Med 1992;327:669-77.
18. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
19. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, et al; Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354:1685-97.
20. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH, Cutler JA Jr, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-85.
21. Kannel WB. Some lessons in cardiovascular epidemiology from Framingham. Am J Cardiol 1976;37:269-82.
22. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2013 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013;3:5-14.
23. American Diabetes Association. Standards of medical care in diabetes: 2013. Diabetes Care 2013;36(suppl 1):S11-66.
24. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 2002;106:3143-421.
25. Criqui MH, McClelland RL, McDermott MM, Allison MA, Blumenthal RS, Aboyans V, et al. The ankle-brachial index and incident cardiovascular events in the MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2010;56:1506-12.
26. McDermott MM, Liu K, Criqui MH, Ruth K, Goff D, Saad MF, et al. Ankle-brachial index and subclinical cardiac and carotid disease: the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol 2005;162:33-41.
27. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB Sr, Gibbons R, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(suppl 2):S49-53.
28. Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology American/Heart Association Task Force on Practice Guidelines. Circulation 2014;129(suppl 2):S76-99.
29. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2014;129(suppl 2): S102-38.
30. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(suppl 2):S1-45.
31. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med 2009;26: 142-8.
32. US Department of Health and Human Services. 2004 Surgeon General's Report: The Health Consequences of Smoking. Atlanta, GA: US Department of Health and Human Services PHS, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004.
33. Goldenberg I, Jonas M, Tenenbaum A, Boyko V, Matetzky S, Shotan A, et al; Bezafibrate Infarction Prevention Study Group. Current smoking, smoking cessation, and the risk of sudden cardiac death in patients with coronary artery disease. Arch Intern Med 2003;163:2301-5.
34. US Department of Health and Human Services. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services PHS, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2006.
35. US Office of the Surgeon General. Reducing the Health Consequences of Smoking: 25 Years of Progress: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services PHS; 1989. P. 89-8411.
36. Isles C, Brown JJ, Cumming AM, Lever AF, McAreavey D, Robertson JI, et al. Excess smoking in malignant-phase hypertension. BMJ 1979;1:579-81.
37. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE; Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142:233-9.
38. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010;303:235-41.
39. Chiang BN, Perlman LV, Epstein FH. Overweight and hypertension: a review. Circulation 1969;39:403-21.
40. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999;282:1523-9.
41. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002;162:1867-72.
42. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-9.
43. Kotchen TA. Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. Am J Hypertens 2010;23:1170-8.
44. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al; ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007;25:1751-62.
45. Sharma AM, Pischon T, Engeli S, Scholze J. Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens 2001;19:667-74.
46. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201-7.
47. Frohlich ED. Clinical management of the obese hypertensive patient. Cardiol Rev 2002;10:127-38.
48. Wenzel UO, Krebs C. Management of arterial hypertension in obese patients. Current Hypertens Rep 2007;9:491-7.
49. Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol 2007;50: 563-72.
50. Anderson JL, Halperin JL, Albert N, Bozkurt B, Brindis RG, Curtis LH, et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:1425-43.
51. Coffman JD. Vasodilator drugs for peripheral vascular disease. N Engl J Med 1979;301:159-60.
52. Roberts DH, Tsao Y, McLoughlin GA, Breckenridge A. Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. Lancet 1987;2:650-3.
53. Solomon SA, Ramsay LE, Yeo WW, Parnell L, Morris-Jones W. Beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. BMJ 1991;303:1100-4.
54. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151:1769-76.
55. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary: a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). Circulation 2006;113:1474-547.
56. US Renal Data System. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2009.
57. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New Engl J Med 2004;351:1296-305.
58. Khouri Y, Steigerwalt SP, Alsamara M, McCullough PA. What is the ideal blood pressure goal for patients with stage III or higher chronic kidney disease? Curr Cardiol Rep 2011;13:492-501.
59. Karohi C, Raggi P. Approach to cardiovascular disease prevention in patients with chronic kidney disease. Curr Treat Options Cardiovasc Med 2012;14: 391-413.
60. Acelajado MC, Calhoun DA, Oparil S. Pathogenesis of hypertension. In: Black H, Elliott W, editors. Hypertension: A Companion to Braunwald's Heart Disease. 2nd ed. Philadelphia, PA: Elsevier Sanders; 2012. P. 12-26.
61. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-83.
62. Katagiri H, Yamada T, Oka Y. Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals. Circ Res 2007;101:27-39.
63. Ding K, Kullo IJ. Genome-wide association studies for atherosclerotic vascular disease and its risk factors. Circ Cardiovasc Genet 2009;2:63-72.
64. Abd El-Aziz TA, Hussein YM, Mohamed RH, Shalaby SM. Renin-angiotensin system genes polymorphism in Egyptians with premature coronary artery disease. Gene 2012;498:270-5.
65. Konopka A, Szperl M, Piotrowski W, Roszczynko M, Ste{ogonek}pińska J. Influence of renin-angiotensin system gene polymorphisms on the risk of ST-segmentelevation myocardial infarction and association with coronary artery disease risk factors. Mol Diagn Ther 2011;15:167-76.
66. Tanner RM, Lynch AL, Brophy VH, Eckfeldt JH, Davis BR, Ford CE, et al. Pharmacogenetic associations of MMP9 and MMP12 variants with cardiovascular disease in patients with hypertension. PLoS One 2011;6:e23609.
67. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the missing heritability of complex diseases. Nature 2009;461: 747-53.
68. Pimenta E, Calhoun DA, Oparil S. Cardiology. In: Crawford MH, Di Marco JP, Paulus WJ, editors. Etiology and Pathogenesis of Systemic Hypertension. 3rd ed. Philadelphia, PA: Elsevier; 2009. P. 511-22.
69. Laurent S, Boutouyrie P. Recent advances in arterial stiffness and wave reflection in human hypertension. Hypertension 2007;49:1202-6.
70. Dao HH, Essalihi R, Bouvet C, Moreau P. Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension. Cardiovasc Res 2005;66:307-17.
71. Franklin SS, Gustin W 4th, Wong ND, Larson MG, Weber MA, Kannel WB, et al. Hemodynamic patterns of age-related changes in blood pressure: the Framingham Heart Study. Circulation 1997;96:308-15.
72. Pimenta E, Oparil S. Management of hypertension in the elderly. Nat Rev Cardiol 2012;9:286-96.
73. O'Rourke MF, Hashimoto J. Mechanical factors in arterial aging: a clinical perspective. J Am Coll Cardiol 2007;50:1-13.
74. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al; European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006;27:2588-605.
75. Wallace SM, Yasmin, McEniery CM, Mäki-Petäjä KM, Booth AD, Cockroft JR, et al. Isolated systolic hypertension is characterized by increased aortic stiffness and endothelial dysfunction. Hypertension 2007;50:228-33.
76. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994;24:1468-74.
77. Stewart KJ, Sung J, Silber HA, Fleg JL, Kelemen MD, Turner KL, et al. Exaggerated exercise blood pressure is related to impaired endothelial vasodilator function. Am J Hypertens 2004;17:314-20.
78. Endtmann C, Ebrahimian T, Czech T, Arfa O, Laufs U, Fritz M, et al. Angiotensin II impairs endothelial progenitor cell number and function in vitro and in vivo: implications for vascular regeneration. Hypertension 2011;58:394-403.
79. Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 2003;24: 471-8.
80. Nickenig G, Sachinidis A, Michaelsen F, Bohm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997;95:473-8.
81. Daugherty A, Rateri DL, Lu H, Inagami T, Cassis LA. Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation 2004;110:3849-57.
82. Singh BM, Mehta JL. Interactions between the reninangiotensin system and dyslipidemia: relevance in the therapy of hypertension and coronary heart disease. Arch Intern Med 2003;163:1296-304.
83. Lemarié CA, Schiffrin EL. The angiotensin II type 2 receptor in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2010;11:19-31.
84. Ali Q, Hussain T. AT2 receptor non-peptide agonist C21 promotes natriuresis in obese Zucker rats. Hypertens Res 2012;35:654-60.
85. Elliott WJ, Ram CV. Calcium channel blockers. J Clin Hypertens (Greenwich) 2011;13:687-9.
86. Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. J Clin Hypertens (Greenwich) 2011;13:639-43.
87. Taylor AA, Siragy H, Nesbitt S. Angiotensin receptor blockers: pharmacology, efficacy and safety. J Clin Hypertens (Greenwich) 2011;13:677-86.
88. Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Mbewu A, Opie LH. Beta-blockers for hypertension. Cochrane Database Syst. Rev 2012;11:CD002003.
89. Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004;65:1991-2002.
90. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
91. Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
92. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28.
93. Effects of treatment on morbidity in hypertension, II: results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970;213: 1143-52.
94. MRC trial of treatment of mild hypertension: principal results: Medical Research Council Working Party. BMJ (Clin Res Ed) 1985;291:97-104.
95. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP): SHEP Cooperative Research Group. JAMA 1991;265:3255-64.
96. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
97. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004;43:963-9.
98. Black HR, Davis B, Barzilay J, Nwachuku C, Baimbridge C, Marginean H, et al; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2008;31:353-60.
99. Cushman WC, Davis BR, Pressel SL, Cutler JA, Einhorn PA, Ford CE, et al; ALLHAT Collaborative Research Group. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich) 2012;14:20-31.
100. Barzilay JI, Davis BR, Pressel SL, Cutler JA, Einhorn PT, Black HR, et al; ALLHAT Collaborative Research Group. Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ Cardiovasc Qual Outcomes 2012;5:153-62.
101. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure: the SOLVD Investigators. N Engl J Med 1991; 325:293-302.
102. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions: the SOLVD Investigators. N Engl J Med 1992;327:685-91.
103. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 1993;329:1456-62.
104. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358: 1033-41.
105. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 2001;38:E28-32.
106. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al; PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351: 2058-68.
107. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al; VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-31.
108. Sica DA. The Valsartan Antihypertensive Long-Term Use Evaluation trial: a study in contrasts. Hypertension 2006;48:362-3.
109. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial: Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-60.
110. Telmisartan Randomised Assessme Nt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174-83.
111. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
112. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348: 1309-21.
113. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364: 11-21.
114. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
115. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, et al; CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003;289:2073-82.
116. Pepine CJ, Handberg EM, Cooper-De Hoff RM, Marks RG, Kowey P, Messerli FH, et al; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16.
117. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-65.
118. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction: the Adverse Experience Committee and the Multicenter Diltiazem Postinfarction Research Group. Circulation 1991;83:52-60.
119. McMurray JJ, Abraham WT, Dickstein K, Køber L, Massie BM, Krum H. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail 2012;14:341-3.
120. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev 2009;CD004349.
121. Elliott WJ. What should be the blood pressure target for diabetics? Curr Opin Cardiol 2011;26:308-13.
122. Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med 2011;154:541-8.
123. Izzo JL Jr, Gradman AH. Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure. Med Clin North Am 2004;88:1257-71.
124. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, et al. Impact of high normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001;345:1291-7.
125. Hsia J, Margolis KL, Eaton CB, Wenger NK, Allison M, Wu L, et al; Women's Health Initiative Investigators. Prehypertension and cardiovascular disease risk in the Women's Health Initiative. Circulation 2007;115:855-60.
126. Fukuhara M, Arima H, Ninomiya T, Hata J, Yonemoto K, Doi Y, et al. Impact of lower range of prehypertension on cardiovascular events in a general population: the Hisayama Study. J Hypertens 2012;30: 893-900.
127. Canty JM Jr. Coronary pressure-function and steadystate pressure-flow relations during autoregulation in the unanesthetized dog. Circ Res 1988;63:821-36.
128. Harrison DG, Florentine MS, Brooks LA, Cooper SM, Marcus ML. The effect of hypertension and left ventricular hypertrophy on the lower range of coronary autoregulation. Circulation 1988;77:1108-15.
129. Rouleau JR, Simard D, Blouin A, Kingma JG Jr. Angiotensin inhibition and coronary autoregulation in a canine model of LV hypertrophy. Basic Res Cardiol 2002;97:384-91.
130. Hoffman JI. Heterogeneity of myocardial blood flow. Basic Res Cardiol 1995;90:103-11.
131. Strauer BE. The concept of coronary flow reserve. J Cardiovasc Pharmacol 1992;19(supp1 5):S67-80.
132. Sipahi I, Tuzcu EM, Schoenhagen P, Wolski KE, Nicholls SJ, Balog C, et al. Effects of normal, prehypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol 2006;48:833-8.
133. Stewart IM. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet 1979;1:861-5.
134. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet 1987;1:581-4.
135. Millar JA, Lever AF. Implications of pulse pressure as a predictor of cardiac risk in patients with hypertension. Hypertension 2000;36:907-11.
136. Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The J-curve phenomenon and the treatment of hypertension: is there a point beyond which pressure reduction is dangerous? JAMA 1991;265: 489-95.
137. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke and coronary heart disease, part 1: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335: 765-74.
138. Denardo SJ, Messerli FH, Gaxiola E, Aranda JM Jr, Cooper-Dehoff RM, Handberg EM, et al. Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST]). Am J Cardiol 2010;106:498-503.
139. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006;144:884-93.
140. Thune JJ, Signorovitch J, Kober L, Velasquez EJ, McMurray JJV, Califf RM, et al. Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. Hypertension 2008;51:48-54.
141. Denardo SJ, Anderson RD, Pepine CJ. Blood pressure targets after high-risk myocardial infarction; is it time to update the guidelines? Hypertension 2008; 51:26-7.
142. Bangalore S, Messerli FH, Wun CC, Zuckerman AL, De Micco D, Kostis JB, et al; Treating to New Targets Steering Committee and Investigators. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J 2010;31:2897-908.
143. Dorresteijn JAN, van der Graaf Y, Spiering W, Grobbee DE, Bots ML, Visseren FLJ; Secondary Manifestations of Arterial Disease Study Group. Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease: J-curve revisited. Hypertension 2012;59:14-21.
144. Waller PC, Isles CG, Lever AF, Murray GD, McInnes GT. Does therapeutic reduction of diastolic blood pressure cause death from coronary heart disease? J Hum Hypertens 1988;2:7-10.
145. Fletcher A, Beevers DG, Bulpitt CJ, Butler A, Coles EC, Hunt D, et al. The relationship between a low treated blood pressure and IHD mortality: a report from the DHSS Hypertension Care Computing Project (DHCCP). J Hum Hypertens 1988;2:11-5.
146. Samuelsson OG, Wilhelmsen LW, Pennert KM, Wedel H, Berglund GL. The J-shaped relationship between coronary heart disease and achieved blood pressure level in treated hypertension: further analyses of 12 years of follow-up of treated hypertensives in the Primary Prevention Trial in Gothenburg, Sweden [published correction appears in J Hypertens.1990;8: following H87]. J Hypertens 1990;8:547-55.
147. Madhavan S, Ooi WL, Cohen H, Alderman MH. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994;23:395-401.
148. Kannel WB, Wilson PW, Nam BH, D'Agostino RB, Li J. A likely explanation for the J-curve of blood pressure cardiovascular risk. Am J Cardiol 2004;94: 380-4.
149. Boutitie F, Gueyffier F, Pocock S, Fagard R, Boissel JP; INDANA Project Steering Committee, Individual Data Analysis of Antihypertensive intervention. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data. Ann Intern Med 2002;136:438-48.
150. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT Study: a randomized controlled trial. JAMA 2004;292:2217-25.
151. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: Harris MI, Cowie CC, Stern MS, Boyko EJ, Reiber GE, Bennett PH, editors. Diabetes in America. 2nd ed. Washington, DC: National Institutes of Health; 1995. P. 429-48.
152. Nilsson PM. ACCORD and risk-factor control in type 2 diabetes. N Engl J Med 2010;362:1628-9.
153. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(suppl 2):B54-64.
154. Lackland DT, Elkind MSV, D'Agostino R, Dhamoon MS, Goff DC Jr, Higashida RT, et al; on behalf of the American Heart Association Stroke Council; Council on Epidemiology and Prevention; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research. Inclusion of stroke in cardiovascular risk prediction instruments: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2012;43:1998-2027.
155. Ovbiagele B, Diener H-C, Yusuf S, Martin RH, Cotton D, Vinisko R, et al. PROFESS Investigators. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA 2011;306: 2137-44.
156. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.
157. Psaty BM, Furburg CD, Kuller LH, Cushman M, Savage PJ, Levine D, et al. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality. Arch Intern Med 2001; 161:1183-92.
158. Denardo SJ, Gong Y, Nichols WW, Messerli FH, Bavry AA, Cooper-De Hoff RM, et al. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Am J Med 2010;123:719-26.
159. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al; ACCF Task Force. ACCF/AHA 2011 expert consensus document on Hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2011;123:2434-506.
160. Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP; PROVE IT-TIMI 22 Trial Investigators. What is the optimal blood pressure in patients after acute coronary syndromes? Relationship of blood pressure and cardiovascular events in the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation 2010;122:2142-51.
161. Cooper-De Hoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010;304:61-8.
162. Banach M, Bhatia V, Feller MA, Mujib M, Desai RV, Ahmed MI, et al. Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol 2011;107:1208-14.
163. Mancia G, Schumacher H, Redon J, Verdecchia P, Scmieder R, Jennings G, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation 2011;124: 1727-36.
164. Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, et al; ONTARGET Investigators. Safety and efficacy of low blood pressures among patients with diabetes. Subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial. J Am Coll Cardiol 2012;59:74-83.
165. Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC, et al. Achievement and safety of a low blood pressure goal in chronic renal disease: the Modification of Diet in Renal Disease Study Group. Hypertension 1997; 29:641-50.
166. Ruggenenti P, Perna A, Loriga G, Ganeva M, Enelordache B, Turturro M, et al; REIN-2 Study Group. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005; 365:939-46.
167. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al; Task Force Members. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-357.
168. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al; World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and the American College of Cardiology Foundation. Circulation 2011;124:2458-73.
169. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al; American College of Cardiology Foundation. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012;126: 3097-137.
170. Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2014; 130:1749-67.
171. Qaseem A, Fihn SD, Dallas P, Williams S, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College of Physicians.. Management of stable ischemic heart disease: summary of a clinical practice guideline from the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. Ann Intern Med 2012;157:735-43.
172. Rosendorff C. Calcium antagonists in the treatment of hypertension in patients with ischaemic heart disease. Expert Opin Pharmacother 2003;4:1535-41.
173. Mason RP. Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis 2002;165: 191-9.
174. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003;362:1527-35.
175. Wing LMH, Reid CM, Ryan R, Beilin LJ, Brown MK, Jennings GLR, et al. Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-92.
176. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary: a report of the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) [published correction appears in Circulation. 2005;111:2013]. Circulation 2004;110:588-636.
177. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2005;112:1825-52.
178. Frazier CG, Shah SH, Armstrong PW, Bhapkar MV, McGuire DK, Sadowski Z, et al; SYMPHONY and the Second SYMPHONY Investigators. Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events Postacute COro-Narys Yndromes (SYMPHONY) randomized clinical trials. Am Heart J 2005;150:1260-7.
179. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000;284:835-42.
180. Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et al; Global Registry of Acute Coronary Events Investigators. Predictors of hospital mortality in the Global Registry of Acute Coronary Events. Arch Intern Med 2003;163:2345-53.
181. Chin CT, Chen AY, Wang TY, Alexander KP, Mathews R, Rumsfeld JS, et al. Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get With The Guidelines (GWTG) acute myocardial infarction mortality model and risk score. Am Heart J 2011;161:113-22.e2.
182. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an Intravenousn PA for Treatment of Infarcting Myocardium Early II Trial substudy. Circulation 2000;102:2031-7.
183. Chang WC, Boersma E, Granger CB, Harrington RA, Califf RM, Simoons ML, et al; GUSTO-IIB and PURSUIT Investigators. Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from GUSTO-IIB and PURSUIT. Am Heart J 2004; 148:62-71.
184. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines) bleeding score. Circulation 2009;119:1873-82.
185. Mathews R, Peterson ED, Chen AY, Wang TY, Chin CT, Fonarow GC, et al. In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: Derivation and validation of a model from the ACTION Registry®-GWTG™. Am J Cardiol 2011;107:1136-43.
186. Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol 2010;55:2556-66.
187. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127: e663-828.
188. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction: Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994;343:1115-22.
189. ISIS-4: randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction: ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995;345:669-85.
190. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al; ACCF/AHA Task Force. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127: 529-55.
191. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease, II: unstable angina, heart failure, primary prevention with aspirin, and risk factor reduction. JAMA 1988;260:2259-63.
192. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1: First International Study of Infarct Survival Collaborative Group. Lancet 1986;2:57-66.
193. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial: the TIMI Study Group. N Engl J Med 1989;320:618-27.
194. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, et al; COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366:1622-32.
195. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for The Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction). Circulation 2007;116:e148-304.
196. Andrus MR, Holloway KP, Clark DB. Use of betablockers in patients with COPD. Ann Pharmacother 2004;38:142-5.
197. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;CD003566.
198. Early treatment of unstable angina in the coronary care unit: a randomised, double blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both: report of the Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Br Heart J 1986; 56:400-13.
199. Verapamil in acute myocardial infarction: the Danish Multicenter Study Group on Verapamil in Myocardial Infarction. Eur Heart J 1984;5:516-28.
200. Hansen JF. Treatment with verapamil after an acute myocardial infarction: a review of the Danish Studies on Verapamil in Myocardial Infarction (DAVIT I and II). Drugs 1991;42(suppl 2):43-53.
201. Hansen JF, Tingsted L, Rasmussen V, Madsen JK, Jespersen CM. Verapamil and angiotensin-converting enzyme inhibitors in patients with coronary artery disease and reduced left ventricular ejection fraction. Am J Cardiol 1996;77:16D-21D.
202. Braunwald E, Pfeffer MA. Ventricular enlargement and remodeling following acute myocardial infarction: mechanisms and management. Am J Cardiol 1991;68:1D-6D.
203. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995;345:686-7.
204. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials: ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 1998;97:2202-12.
205. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure: the Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342:821-8.
206. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction: Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333:1670-6.
207. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-51.
208. Katz JN, Gore JM, Amin A, Anderson FA, Dasta JF, Ferguson JJ, et al; STAT Investigators. Practice patterns, outcomes, and end-organ dysfunction for patients with acute severe hypertension: the Studying the Treatment of Acute Hypertension (STAT) Registry. Am Heart J 2009;158:599-606.e1.
209. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:e391-479.
210. Adams KF Jr, Fonarow GC, Emerman CL, Le Jemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149: 209-16.
211. Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation 2010;122:585-96.
212. O'Connor CM, Velazquez EJ, Gardner LH, Smith PK, Newman MF, Landolfo KP, et al. Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (a 25-year experience from the Duke Cardiovascular Disease Databank). Am J Cardiol 2002;90:101-7.
213. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991;121(pt 1):951-7.
214. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971;285:1441-6.
215. Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med 1985;312:277-83.
216. Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure: mechanisms and management. Ann Intern Med 1992; 117:502-10.
217. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996;275:1557-62.
218. Wilhelmsen L, Rosengren A, Eriksson H, Lappas G. Heart failure in the general population of men: morbidity, risk factors and prognosis. J Intern Med 2001;249:253-61.
219. Kostis JB, Davis BR, Cutler J, Grimm RH Jr, Berge KG, Cohen JD, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension: SHEP Cooperative Research Group. JAMA 1997;278:212-6.
220. Felker GM, Adams KF Jr, Konstam MA, O'Connor CM, Gheorghiade M. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am Heart J 2003; 145(suppl):S18-25.
221. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, et al. Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med 1999;159:29-34.
222. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996;27:1214-8.
223. Diez J, Fortuno MA, Ravassa S. Apoptosis in hypertensive heart disease. Curr Opin Cardiol 1998;13: 317-25.
224. Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol 2004;43:2207-15.
225. Drazner MH. The progression of hypertensive heart disease. Circulation 2011;123:327-34.
226. Shapiro BP, Owan TE, Mohammed S, Kruger M, Linke WA, Burnett JC Jr, et al. Mineralocorticoid signaling in transition to heart failure with normal ejection fraction. Hypertension 2008;51:289-95.
227. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006;113:2089-96.
228. Zile MR, Bennett TD, St John Sutton M, Cho YK, Adamson PB, Aaron MF, et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation 2008;118:1433-41.
229. Melenovsky V, Borlaug BA, Rosen B, Hay I, Ferruci L, Morell CH, et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol 2007;49: 198-207.
230. Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 2007;115:1982-90.
231. Borlaug BA, Lam CS, Roger VL, Rodeheffer RJ, Redfield MM. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 2009;54:410-8.
232. Kramer K, Kirkman P, Kitzman D, Little WC. Flash pulmonary edema: association with hypertension and reoccurrence despite coronary revascularization. Am Heart J 2000;140:451-5.
233. Goldberger JJ, Peled HB, Stroh JA, Cohen MN, Frishman WH. Prognostic factors in acute pulmonary edema. Arch Intern Med 1986;146:489-93.
234. Clark LT, Garfein OB, Dwyer EM Jr. Acute pulmonary edema due to ischemic heart disease without accompanying myocardial infarction: natural history and clinical profile. Am J Med 1983;75:332-6.
235. Dodek A, Kassebaum DG, Bristow JD. Pulmonary edema in coronary-artery disease without cardiomegaly: paradox of the stiff heart. N Eng J Med 1972; 286:1347-50.
236. Chin MH, Goldman L. Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Arch Intern Med 1996;156: 1814-20.
237. Zampaglione B, Pascale C, Marchisio M, Cavallo-Perin P. Hypertensive urgencies and emergencies: prevalence and clinical presentation. Hypertension 1996;27:144-7.
238. Belardinelli R, Georgiou D, Purcaro A. Low dose dobutamine echocardiography predicts improvement in functional capacity after exercise training in patients with ischemic cardiomyopathy: prognostic implication. J Am Coll Cardiol 1998;31:1027-34.
239. Specchia G, De Servi S, Scire A, Assandri J, Berzuini C, Angoli L, et al. Interaction between exercise training and ejection fraction in predicting prognosis after a first myocardial infarction. Circulation 1996;94:978-82.
240. O'Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, et al; HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009;301:1439-50.
241. Flynn KE, Pina IL, Whellan DJ, Lin L, Blumenthal JA, Ellis SJ, et al; HF-ACTION Investigators. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009;301:1451-9.
242. Fletcher GF, Balady GJ, Amsterdam EA, Chaitman B, Eckel R, Fleg J, et al. Exercise standards for testing and training: a statement for healthcare professionals from the American Heart Association. Circulation 2001;104:1694-740.
243. Shephard RJ, Balady GJ. Exercise as cardiovascular therapy. Circulation 1999;99:963-72.
244. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001;358:1305-15.
245. Neuberg GW, Miller AB, O'Connor CM, Belkin RN, Carson PE, Cropp AB, et al; PRAISE Investigators, Prospective Randomized Amlodipine Survival Evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002;144:31-8.
246. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohumoral axis. Ann Intern Med 1985;103:1-6.
247. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987;57:17-22.
248. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al; NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011;364:797-805.
249. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: results of the SOLVD echocardiography substudy. Circulation 1995;91:2573-81.
250. Longobardi G, Ferrara N, Furgi G, Abete P, Rengo F. Improvement of myocardial blood flow to ischemic regions by angiotensin-converting enzyme inhibition. J Am Coll Cardiol 2000;36:1437-8.
251. Leesar MA, Jneid H, Tang XL, Bolli R. Pretreatment with intracoronary enalaprilat protects human myocardium during percutaneous coronary angioplasty. J Am Coll Cardiol 2007;49:1607-10.
252. Minai K, Matsumoto T, Horie H, Ohira N, Takashima H, Yokohama H, et al. Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin converting enzyme inhibitors. J Am Coll Cardiol 2001;37:1565-70.
253. Gustafsson F, Torp-Pedersen C, Kober L, Hildebrandt P. Effect of angiotensin converting enzyme inhibition after acute myocardial infarction in patients with arterial hypertension: TRACE Study Group, Trandolapril Cardiac Event. J Hypertens 1997;15:793-8.
254. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure: Atlas Study Group. Circulation 1999;100:2312-8.
255. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
256. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, et al; Collaborative Study Group. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005;16:2170-9.
257. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.
258. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
259. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-convertingenzyme inhibitors: the CHARM-Alternative Trial. Lancet 2003;362:772-6.
260. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved leftventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-81.
261. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66.
262. White HD. Candesartan and heart failure: the allure of CHARM. Lancet 2003;362:754-5.
263. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-convertingenzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71.
264. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001-7.
265. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
266. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation 2002;106: 2194-9.
267. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure: MOCHA Investigators. Circulation 1996;94: 2807-16.
268. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26: 215-25.
269. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al; Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13.
270. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, et al; African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-57.
271. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 128:1810-52.
272. Kandler MR, Mah GT, Tejani AM, Stabler SN, Salzwedel DM. Hydralazine for essential hypertension. Cochrane Database Syst Rev 2011;CD004934.
273. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al; Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrin Metab 2008;93:3266-81.
274. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373:1275-81.
275. SYMPLICITY HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLIC ITY HTN-2 trial): a randomised controlled trial. Lancet 2010;376:1903-9.
276. Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Bohm M, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012;59:901-9.
277. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, et al; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014;370: 1393-401.
278. Moss AJ, Oakes D, Benhorin J, Carleen E. The interaction between diltiazem and left ventricular function after myocardial infarction: Multicenter Diltiazem Post-Infarction Research Group. Circulation 1989; 80(suppl):IV102-6.
279. O'Connor CM, Carson PE, Miller AB, Pressler ML, Belkin RN, Neuberg GW, et al. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE Trial: Prospective Randomized Amlodipine Survival Evaluation. Am J Cardiol 1998; 82:881-7.
280. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HEFT III: Vasodilator-Heart Failure Trial (V-HEFT) Study Group. Circulation 1997;96: 856-63.
281. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, et al; MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003;5:659-67.
282. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALLHAT Collaborative Research Group. JAMA 2000;283:1967-75.
283. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121:289-300.
284. Whelton A. Nephrotoxicity of nonsteroidal antiinflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999;106:13S-24S.